Cited by 1,463Lipoproteins and Cardiovascular HealthPharmacovigilance and Adverse Drug ReactionsMuscle and Compartmental Disorders

The DOI matches its Crossref record; 103 of the 114 references it cites were found in a registry or an index.

Statin-Associated Myopathy

Thompson, Paul D., Clarkson, Priscilla, Karas, Richard H.·2003·JAMA

DOI 10.1001/jama.289.13.1681

Open this paper in CoChat — free account

Abstract

Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) are associated with skeletal muscle complaints, including clinically important myositis and rhabdomyolysis, mild serum creatine kinase (CK) elevations, myalgia with and without elevated CK levels, muscle weakness, muscle cramps, and persistent myalgia and CK elevations after statin withdrawal. We performed a literature review to provide a clinical summary of statin-associated myopathy and discuss possible mediating mechanisms. We also update the US Food and Drug Administration (FDA) reports on statin-associated rhabdomyolysis. Articles on statin myopathy were identified via a PubMed search through November 2002 and articles on statin clinical trials, case series, and review articles were identified via a PubMed search through January 2003. Adverse event reports of statin-associated rhabdomyolysis were also collected from the FDA MEDWATCH database. The literature review found that reports of muscle problems during statin clinical trials are extremely rare. The FDA MEDWATCH Reporting System lists 3339 cases of statin-associated rhabdomyolysis reported between January 1, 1990, and March 31, 2002. Cerivastatin was the most commonly implicated statin. Few data are available regarding the frequency of less-serious events such as muscle pain and weakness, which may affect 1% to 5% of patients. The risk of rhabdomyolysis and other adverse effects with statin use can be exacerbated by several factors, including compromised hepatic and renal function, hypothyroidism, diabetes, and concomitant medications. Medications such as the fibrate gemfibrozil alter statin metabolism and increase statin plasma concentration. How statins injure skeletal muscle is not clear, although recent evidence suggests that statins reduce the production of small regulatory proteins that are important for myocyte maintenance.

Integrity signals

Registry

Crossref · 10.1001/jama.289.13.1681

Cites

103 of 103 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial
(2002) · The Lancet · doi:10.1016/s0140-6736(02)09327-3 · Cited by 6,992
Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels: Results of AFCAPS/TexCAPS
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
SCANDINAVIANSIMVASTATINSURVIVAL (1994) · The Lancet · doi:10.1016/s0140-6736(94)90566-5 · Cited by 3,638
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453

Show all 114 references

Research works printed but not linked: 9

Fuhrmans, 2002, Bayer discloses higher death toll from Baycol., Wall Street Journal, A10
Hamilton-Craig, 2001, Statin-associated myopathy., Med J Aust, 175, 486, 10.5694/mja2.2001.175.issue-9 · DOI
Omar, 2002, FDA adverse event reports on statin-associated rhabdomyolysis., Ann Pharmacother, 36, 288, 10.1345/aph.1A289 · DOI · Paper page
GISSI Prevenzione Investigators, 2000, Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico)?, Ital Heart J, 1, 810
Omar, 2001, Rhabdomyolysis and HMG-CoA reductase inhibitors., Ann Pharmacother, 35, 1096, 10.1345/aph.10228 · DOI · Paper page
Shek, 2001, Statin-fibrate combination therapy., Ann Pharmacother, 35, 908, 10.1345/aph.10315 · DOI · Paper page
Prueksaritanont, 2002, Metabolic interactions between gemfibrozil and statins in human liver preparations [abstract]., Circulation, 106, II185
Not Available, 2001, Cardiovascular Trials Review
Not Available, 2002, Cardiovascular Trials Review

Sorted by citations

Items 301–400 of 1,001

Long-Term Statin Treatment in Children with Familial Hypercholesterolemia: More Insight into Tolerability and Adherence
Braamskamp, M. J. A. M., Kusters, D. M., Avis, H. J., Smets, E. M. A., Wijburg, F. A., Kastelein, J. J. P., Wiegman, A., & Hutten, B. A. (2015) · Pediatric Drugs · doi:10.1007/s40272-014-0116-y · Cited by 61
Statin Withdrawal: Clinical Implications and Molecular Mechanisms
Cubeddu, L. X., & Seamon, M. J. (2006) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.9.1288 · Cited by 59
Update on Toxic Myopathies
Mastaglia, F. L., & Needham, M. (2011) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-011-0232-9 · Cited by 59
The Impact of Dietary Changes and Dietary Supplements on Lipid Profile
Huang, J., Frohlich, J. J., & Ignaszewski, A. P. (2011) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2010.12.077 · Cited by 60
Considerations for safe use of statins: liver enzyme abnormalities and muscle toxicity.
Gillett, R. C., & Norrell, A. (2011) · PubMed · Cited by 62
Association between SLCO1B1 T521C polymorphism and risk of statin-induced myopathy: a meta-analysis
Xiang, Q., Chen, S.-Q., Ma, L., Hu, K., Zhang, Z., Mu, G., Xie, Q., Zhang, X., & Cui, Y. (2018) · The Pharmacogenomics Journal · doi:10.1038/s41397-018-0054-0 · Cited by 60
Statin myotoxicity is associated with changes in the cardiopulmonary function
Phillips, P. S., Phillips, C. T., Sullivan, M. J., Naviaux, R. K., & Haas, R. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.06.014 · Cited by 59
Agents and mechanisms of toxic myopathy
Kuncl, R. W. (2009) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32833045a0 · Cited by 58
Fenofibrate: a novel formulation (Triglide?) in the treatment of lipid disorders: a review
Τζιόμαλος, Κ., & Athyros, V. G. (2006) · International Journal of Nanomedicine · doi:10.2147/nano.2006.1.2.129 · Cited by 58
Safety Issues with Statin Therapy
Talbert, R. L. (2006) · Journal of the American Pharmacists Association · doi:10.1331/154434506778073637 · Cited by 58
Statin myopathy: an update
Christopher‐Stine, L. (2006) · Current Opinion in Rheumatology · doi:10.1097/01.bor.0000245730.25383.97 · Cited by 56
Pharmacogenomic and pharmacogenetic-guided therapy as a tool in precision medicine: current state and factors impacting acceptance by stakeholders
Hess, G. P., Fonseca, E., SCOTT, R., & Fagerness, J. A. (2015) · Genetics Research · doi:10.1017/s0016672315000099 · Cited by 57
Pharmacogenomics: candidate gene identification, functional validation and mechanisms
Wang, L., & Weinshilboum, R. M. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn270 · Cited by 57
The Mevalonate Pathway Is Indispensable for Adipocyte Survival
Yeh, Y., Jheng, H., Iwase, M., Kim, M., Mohri, S., Kwon, J., Kawarasaki, S., Li, Y., Takahashi, H., Ara, T., et al. (2018) · iScience · doi:10.1016/j.isci.2018.10.019 · Cited by 57
Membrane cholesterol modulates dihydropyridine receptor function in mice fetal skeletal muscle cells
Pouvreau, S., Berthier, C., Blaineau, S., Amsellem, J., Coronado, R., & Strube, C. (2004) · The Journal of Physiology · doi:10.1113/jphysiol.2003.055285 · Cited by 57
Polymyosites induites ou associées aux traitements hypolipémiants ?
Fauchais, A. L., Ba, J. I., Maurage, P., Kyndt, X., Bataille, D., HACHULLA, E., Parent, D., Queyrel, V., Lambert, M., Pasturel, U. M., et al. (2003) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2003.10.013 · Cited by 57
State of the Art Comprehensive Review of Individual Statins, Their Differences, Pharmacology, and Clinical Implications
Azemawah, V., Movahed, M. R., Centuori, P., Penaflor, R., Riel, P. L., Situ, S., Shadmehr, M., & Hashemzadeh, M. (2019) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-019-06904-x · Cited by 58
The effects of statins on skeletal muscle strength and exercise performance
Krishnan, G. M., & Thompson, P. D. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32833c1edf · Cited by 55
Self-citation
Moderately increased protein intake predominately from egg sources does not influence whole body, regional, or muscle composition responses to resistance training in older people
Iglay, H. B., Apolzan, J. W., Gerrard, D. E., Eash, J. K., Anderson, J. C., & Campbell, W. W. (2009) · The journal of nutrition health & aging · doi:10.1007/s12603-009-0016-y · Cited by 56
Treatment of hyperlipidaemia with fenofibrate and related fibrates
Filippatos, T. D., & Milionis, H. J. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.10.1599 · Cited by 57
OATP1B1-related drug–drug and drug–gene interactions as potential risk factors for cerivastatin-induced rhabdomyolysis
Tamraz, B., Fukushima, H., Wolfe, A. R., Kaspera, R., Totah, R. A., Floyd, J. S., Ma, B., Chu, C., Marciante, K. D., Heckbert, S. R., et al. (2013) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3283620c3b · Cited by 57
Overcoming Challenges With Statin Therapy
Spence, J. D., & Dresser, G. K. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.002497 · Cited by 57
Statins for the prevention of perioperative cardiovascular complications in vascular surgery
Schouten, O., Bax, J. J., Dunkelgrün, M., Feringa, H. H. H., van Urk, H., & Poldermans, D. (2006) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2006.04.039 · Cited by 56
Clinical characterization and molecular mechanisms of statin myopathy
Toth, P. P., Harper, C. R., & Jacobson, T. A. (2008) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.6.7.955 · Cited by 55
Statins in nonsurgical and surgical periodontal therapy. A systematic review and meta‐analysis of preclinical in vivo trials
Bertl, K., Steiner, I. M., Pandis, N., Buhlin, K., Klinge, B., & Stavropoulos, A. (2017) · Journal of Periodontal Research · doi:10.1111/jre.12514 · Cited by 55
Drug-Induced Musculoskeletal Disorders
Bannwarth, B. (2007) · Drug Safety · doi:10.2165/00002018-200730010-00004 · Cited by 54
Diet First, Then Medication for Hypercholesterolemia
Anderson, J. W. (2003) · JAMA · doi:10.1001/jama.290.4.531 · Cited by 55
No effect of combined coenzyme Q10 and selenium supplementation on atorvastatin-induced myopathy
Bogsrud, M. P., Langslet, G., Ose, L., Arnesen, K.-E., Sm stuen, M. C., Malt, U. F., Woldseth, B., & Retterstøl, K. (2013) · Scandinavian Cardiovascular Journal · doi:10.3109/14017431.2012.756119 · Cited by 53
Atherosclerotic plaque-targeted nanotherapeutics ameliorates atherogenesis by blocking macrophage-driven inflammation
Yang, H., Liu, C., Wu, Y., Yuan, M., Huang, J., Xia, Y., Ling, Q., Hoffmann, P. R., Huang, Z., & Chen, T. (2021) · Nano Today · doi:10.1016/j.nantod.2021.101351 · Cited by 54
The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study
de Keyser, C. E., Peters, B. J. M., Becker, M. L., Visser, L. E., Uitterlinden, A. G., Klungel, O. H., Verstuyft, C., Albert Hofman, D., der Zee, A. H. M., & Stricker, B. H. C. (2013) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000018 · Cited by 53
Rosuvastatin 5 and 10 mg/d: A pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach ldl cholesterol goals with nonstatin lipid-lowering therapies
Glueck, C. J., Aregawi, D., Agloria, M., Khalil, Q., Winiarska, M., Munjal, J., Gogineni, S., & Wang, P. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.06.004 · Cited by 73
A comprehensive pharmacogenomic study indicates roles for SLCO1B1, ABCG2 and SLCO2B1 in rosuvastatin pharmacokinetics
Lehtisalo, M., Taskinen, S., Tarkiainen, E. K., Neuvonen, M., Viinamäki, J., Paile‐Hyvärinen, M., Lilius, T. O., Tapaninen, T., Backman, J. T., Tornio, A., et al. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15485 · Cited by 55
Combination therapy in dyslipidemia: Where are we now?
Catapano, A. L., Farnier, M., Foody, J. M., Toth, P. P., Tomassini, J. E., Brudi, P., & Tershakovec, A. M. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.09.026 · Cited by 52
Paraoxonase (PON1 and PON3) Polymorphisms: Impact on Liver Expression and Atorvastatin-Lactone Hydrolysis
Riedmaier, S., Klein, K., Winter, S., Hofmann, U., Schwab, M. G., & Zanger, U. M. (2011) · Frontiers in Pharmacology · doi:10.3389/fphar.2011.00041 · Cited by 53
Rhabdomyolysis and exercise-associated hyponatremia in ultra-bikers and ultra-runners
Chlíbková, D., Knechtle, B., Rosemann, T. J., Tomášková, I., Novotný, J., Žákovská, A., & Uher, T. (2015) · Journal of the International Society of Sports Nutrition · doi:10.1186/s12970-015-0091-x · Cited by 52
Support of drug therapy using functional foods and dietary supplements: focus on statin therapy
Eussen, S. R. B. M., Klungel, O. H., Garssen, J., Verhagen, H., van Kranen, H. J., Loveren, H. V., & Rompelberg, C. J. M. (2010) · British Journal Of Nutrition · doi:10.1017/s0007114509993230 · Cited by 52
Statins and fenofibrate affect skeletal muscle chloride conductance in rats by differently impairing ClC‐1 channel regulation and expression
Pierno, S., Camerino, G. M., Cippone, V., Rolland, J., Desaphy, J., Luca, A. D., Liantonio, A., Bianco, G., Kunic, J., George, A. L., et al. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00079.x · Cited by 52
Neuromuscular Symptoms and Elevated Creatine Kinase after Statin Withdrawal
Echaniz‐Laguna, A., Mohr, M., & Tranchant, C. (2010) · New England Journal of Medicine · doi:10.1056/nejmc0908215 · Cited by 52
Statins Provoking MELAS Syndrome
Thomas, J. E., Lee, N., & Thompson, P. D. (2007) · European Neurology · doi:10.1159/000101287 · Cited by 52
Self-citation
Systematic review and meta‐analysis of clinically relevant adverse events from HMG CoA reductase inhibitor trials worldwide from 1982 to present
McClure, D. L., Valuck, R. J., Glanz, M., & Hokanson, J. E. (2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1341 · Cited by 52
Colesevelam HCl and Ezetimibe Combination Therapy Provides Effective Lipid-Lowering in Difficult-to-Treat Patients with Hypercholesterolemia
Zema, M. J. (2005) · American Journal of Therapeutics · doi:10.1097/01.mjt.0000155109.69831.a3 · Cited by 52
Randomised clinical trial: simvastatin as adjuvant therapy improves significantly the H elicobacter pylori eradication rate ‐ a placebo‐controlled study
Nseir, W., Diab, H., Mahamid, M., Abu‐Elheja, O., Samara, M., Abid, A., & Mograbi, J. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2012.05161.x · Cited by 51
Overcoming ???Ageism??? Bias in the Treatment of Hypercholesterolaemia
Jacobson, T. A. (2006) · Drug Safety · doi:10.2165/00002018-200629050-00005 · Cited by 52
Advances in Understanding Drug-Induced Neuropathies
Peltier, A., & Russell, J. W. (2006) · Drug Safety · doi:10.2165/00002018-200629010-00002 · Cited by 51
Rosuvastatin: Characterization of Induced Myopathy in the Rat
Westwood, F. R., Scott, R. C., Marsden, A. M., Bigley, A. L., & Randall, K. (2008) · Toxicologic Pathology · doi:10.1177/0192623307311412 · Cited by 51
Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia
McKenney, J. M., Jones, M., & Abby, S. L. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x59157 · Cited by 51
Colesevelam Hydrochloride-Ezetimibe Combination Lipid-Lowering Therapy in Patients with Diabetes or Metabolic Syndrome and a History of Statin Intolerance
Rivers, S. M., Kane, M. P., Busch, R. S., Bakst, G., & Hamilton, R. A. (2007) · Endocrine Practice · doi:10.4158/ep.13.1.11 · Cited by 50
Ezetimibe-associated myopathy in monotherapy and in combination with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor
Simard, C., & Poirier, P. (2006) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(06)70253-7 · Cited by 51
Review of Primary and Secondary Prevention Trials with Lovastatin, Pravastatin, and Simvastatin
Gotto, A. M. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.06.010 · Cited by 50
Expert opinion: the therapeutic challenges faced by statin intolerance
Patel, J., Martin, S. S., & Banach, M. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1197202 · Cited by 51
High fat diets and pathology in the guinea pig. Atherosclerosis or liver damage?
Ye, P., Cheah, I. K.-M., & Halliwell, B. B. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.11.008 · Cited by 50
Myopathy during statin therapy in the daily practice of an outpatient cardiology clinic: prevalence, predictors and relation with vitamin D
Riphagen, I. J., van der Veer, E., Muskiet, F. A. J., & DeJongste, M. J. L. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.702102 · Cited by 49
Statins and Modulation of Oxidative Stress
Bełtowski, J. (2005) · Toxicology Mechanisms and Methods · doi:10.1080/15376520590918766 · Cited by 49
Underappreciated Statin-Induced Myopathic Weakness Causes Disability
Dobkin, B. H. (2005) · Neurorehabilitation and neural repair · doi:10.1177/1545968305277167 · Cited by 48
Vaccine Against PCSK9 Improved Renal Fibrosis by Regulating Fatty Acid β‐Oxidation
Wu, D., Zhou, Y., Pan, Y., Li, C., Wang, Y., Chen, F., Chen, X., Yang, S., Zhou, Z., Liao, Y., et al. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.014358 · Cited by 48
Beneficial Effects of Spirulina Supplementation in the Management of Cardiovascular Diseases
Prete, V., Abate, A. C., Pietro, P. D., Lucia, M. D., Vecchione, C., & Carrizzo, A. (2024) · Nutrients · doi:10.3390/nu16050642 · Cited by 54
Pathophysiology, Diagnosis, and Management of Dyslipidemia
Gau, G. T., & Wright, R. S. (2006) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2006.03.001 · Cited by 49
Biomarkers of Drug-Induced Skeletal Muscle Injury in the Rat: Troponin I and Myoglobin
Vassallo, J. D., Janovitz, E. B., Wescott, D. M., Chadwick, C., Lowe‐Krentz, L. J., & Lehman‐McKeeman, L. D. (2009) · Toxicological Sciences · doi:10.1093/toxsci/kfp166 · Cited by 48
Do statins induce or protect from acute kidney injury and chronic kidney disease: An update review in 2018
Verdoodt, A., Honoré, P. M., Jacobs, R., Waele, E. D., Gorp, V. V., Regt, J. D., & Spapen, H. D. (2018) · Journal of Translational Internal Medicine · doi:10.2478/jtim-2018-0005 · Cited by 50
Variation of serum creatine kinase (CK) levels and prevalence of persistent hyperCKemia in a Norwegian normal population. The Tromsø Study
Lilleng, H., Abeler, K., Johnsen, S. H., Stensland, E., Løseth, S., Jorde, R., Figenschau, Y., Lindal, S., Wilsgaard, T., & Bekkelund, S. I. (2011) · Neuromuscular Disorders · doi:10.1016/j.nmd.2011.04.007 · Cited by 47
Diplopia, Blepharoptosis, and Ophthalmoplegia and 3-Hydroxy-3-Methyl-Glutaryl-CoA Reductase Inhibitor Use
Fraunfelder, F. W., & Richards, A. B. (2008) · Ophthalmology · doi:10.1016/j.ophtha.2008.08.006 · Cited by 47
Decreasing LDL Cholesterol and Medication Cost With Every‐Other‐Day Statin Therapy
Juszczyk, M. A., Seip, R. L., & Thompson, P. D. (2005) · Preventive Cardiology · doi:10.1111/j.0197-3118.2005.04404.x · Cited by 47
Self-citation
Increased autophagy accelerates colchicine-induced muscle toxicity
Ching, J. K., Ju, J.-S., Pittman, S. K., Margeta, M., & Weihl, C. C. (2013) · Autophagy · doi:10.4161/auto.26150 · Cited by 47
A Proposal for a Pharmacokinetic Interaction Significance Classification System (PISCS) Based on Predicted Drug Exposure Changes and Its Potential Application to Alert Classifications in Product Labelling
Hisaka, A., Kusama, M., Ohno, Y., Sugiyama, Y., & Suzuki, H. (2009) · Clinical Pharmacokinetics · doi:10.2165/11317220-000000000-00000 · Cited by 47
Rhabdomyolysis in a Patient with Severe Hypothyroidism
Salehi, N., Agoston, E., Munir, I., & Thompson, G. J. (2017) · American Journal of Case Reports · doi:10.12659/ajcr.904691 · Cited by 47
Risk Factors for Rhabdomyolysis with Simvastatin and Atorvastatin
Ronaldson, K. J., Shea, J. M. O., & Boyd, I. W. (2006) · Drug Safety · doi:10.2165/00002018-200629110-00005 · Cited by 47
Acute Rhabdomyolysis Associated with Ofloxacin/Levofloxacin Therapy
Hsiao, S., Chang, C., Tsao, C., Lee, Y.-Y. J., Hsu, M.-Y., & Wu, T.-J. (2004) · Annals of Pharmacotherapy · doi:10.1345/aph.1e285 · Cited by 47
Statin-Induced Myopathy: The Two Faces of Janus
Arora, R. R., Liebo, M., & Maldonado, F. A. (2006) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248406288758 · Cited by 47
Organic anion transporting polypeptides: Pharmacology, toxicology, structure, and transport mechanisms.
Hagenbuch, B., Stieger, B., & Locher, K. (2024) · Pharmacological Reviews · doi:10.1016/j.pharmr.2024.100023 · Cited by 49
Translational insight into statin-induced muscle toxicity: from cell culture to clinical studies
Taha, D. A., de Moor, C. H., Barrett, D. A., & Gershkovich, P. (2014) · Translational research · doi:10.1016/j.trsl.2014.01.013 · Cited by 45
Lovastatin attenuates nerve injury in an animal model of Guillain–Barré syndrome
Sarkey, J. P., Richards, M. P., & Stubbs, E. B. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04309.x · Cited by 44
Rhabdomyolysis in Community Acquired Bacterial Sepsis – A Retrospective Cohort Study
Kumar, A. A., Bhaskar, E. M., Shantha, G. P. S., Swaminathan, P., & Abraham, G. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007182 · Cited by 45
Statin myopathy
Radcliffe, K. A., & Campbell, W. W. (2008) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-008-0011-4 · Cited by 45
Role of statin therapy in the coronary bypass patient
Lazar, H. L. (2004) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2003.12.041 · Cited by 45
Single intra‐articular injection of fluvastatin‐PLGA microspheres reduces cartilage degradation in rabbits with experimental osteoarthritis
Goto, N., Okazaki, K., Akasaki, Y., Ishihara, K., Murakami, K., Koyano, K., Ayukawa, Y., Yasunami, N., Masuzaki, T., & Nakashima, Y. (2017) · Journal of Orthopaedic Research® · doi:10.1002/jor.23562 · Cited by 44
Safety of ezetimibe in lipid-lowering treatment: systematic review and meta-analysis of randomised controlled trials and cohort studies
Wang, Y., Zhan, S., Du, H., Li, J., Khan, S. U., Aertgeerts, B., Guyatt, G. H., Hao, Q., Bekkering, G. E., Li, L., et al. (2022) · BMJ Medicine · doi:10.1136/bmjmed-2022-000134 · Cited by 44
Imaging of Zebrafish In Vivo with Second-Harmonic Generation Reveals Shortened Sarcomeres Associated with Myopathy Induced by Statin
Huang, S., Hsiao, C., Lin, D., Chow, C.-Y., Chang, C.-J., & Liau, I. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024764 · Cited by 44
The Role of Red Yeast Rice for the Physician
Gordon, R. Y., & Becker, D. J. (2010) · Current Atherosclerosis Reports · doi:10.1007/s11883-010-0145-0 · Cited by 45
The role of vitamin D and SLCO1B1 gene polymorphism in statin-associated myalgias
Linde, R., Peng, L., Desai, M., & Feldman, D. (2010) · Dermato-Endocrinology · doi:10.4161/derm.2.2.13509 · Cited by 44
Dyslipidemia in Special Ethnic Populations
Pu, J., Romanelli, R. J., Zhao, B., Azar, K. M. J., Hastings, K. G., Nimbal, V. C., Fortmann, S. P., & Palaniappan, L. P. (2015) · Cardiology Clinics · doi:10.1016/j.ccl.2015.01.005 · Cited by 45
Health plan administrative databases can efficiently identify serious myopathy and rhabdomyolysis
Andrade, S. E., Graham, D. J., Staffa, J. A., Schech, S. D., Shatin, D., Grenade, L. L., Goodman, M. J., Platt, R. G., Gurwitz, J. H., & Chan, K. A. (2005) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2004.10.004 · Cited by 44
Proximal myopathy: diagnostic approach and initial management
Suresh, E., & Wimalaratna, S. (2013) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2013-131752 · Cited by 44
Physiogenomic Analysis Links Serum Creatine Kinase Activities During Statin Therapy to Vascular Smooth Muscle Homeostasis
Ruaño, G., Thompson, P. D., Windemuth, A., Smith, A. P., Kocherla, M., Holford, T. R., Seip, R. L., & Wu, A. H. B. (2005) · Pharmacogenomics · doi:10.2217/14622416.6.8.865 · Cited by 45
Self-citation
Treatment of Dyslipidemia with Statins and Physical Exercises: Recent Findings of Skeletal Muscle Responses
Bonfim, M. R., Oliveira, A. S. B., Amaral, S. L., & Monteiro, H. L. (2015) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20150005 · Cited by 43
Design and synthesis of novel indole-chalcone fibrates as lipid lowering agents
Sashidhara, K. V., Dodda, R. P., Sonkar, R., Palnati, G. R., & Bhatia, G. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.04.085 · Cited by 44
Jatrorrhizine hydrochloride attenuates hyperlipidemia in a high-fat diet-induced obesity mouse model
Yang, W., She, L., Yu, K., Yan, S., Zhang, X., Tian, X., Ma, S., & Zhang, X. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5634 · Cited by 44
The effects of statins on exercise and physical activity
Noyes, A. M., & Thompson, P. D. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.07.003 · Cited by 44
Self-citation
SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case–control study
Liu, J., Liu, X., Chen, S., Zhang, Y., Cai, L., Yang, M., Lai, W., Ren, B., & Zhong, S. (2017) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-017-2318-z · Cited by 44
Hypolipidemic Effect of Arthrospira (Spirulina) maxima Supplementation and a Systematic Physical Exercise Program in Overweight and Obese Men: A Double-Blind, Randomized, and Crossover Controlled Trial
Hernández-Lepe, M. A., Wall‐Medrano, A., López‐Díaz, J. A., Juárez-Oropeza, M. A., Luqueño-Bocardo, O. I., Hernández‐Torres, R. P., & Ramos‐Jiménez, A. (2019) · Marine Drugs · doi:10.3390/md17050270 · Cited by 49
Pharmacogenetics and pharmacogenomics of cholesterol-lowering therapy
Schmitz, G., Schmitz-Mądry, A., & Ugocsai, P. (2007) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3280555083 · Cited by 44
HMG-CoA Reductase Inhibitors (statins) might Cause High Elevations of Creatine Phosphokinase (CK) in Patients with Unnoticed Hypothyroidism
Tokinaga, K., Toru, O. E. D. A., Suzuki, Y., & MATSUSHIMA, Y. (2006) · Endocrine Journal · doi:10.1507/endocrj.k04-144 · Cited by 44
Statins and Peripheral Arterial Disease: Effects on Claudication, Disease Progression, and Prevention of Cardiovascular Events
Coppola, G., & Novo, S. (2007) · Archives of Medical Research · doi:10.1016/j.arcmed.2006.12.012 · Cited by 44
Drug-induced myopathies
Bannwarth, B. (2002) · Expert Opinion on Drug Safety · doi:10.1517/14740338.1.1.65 · Cited by 44
Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin‐Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti‐ PCSK9 Antibody in Statin‐Intolerant Subjects 3 ( GAUSS ‐3) Trial
Nissen, S. E., Dent-Acosta, R. E., Rosenson, R. S., Stroes, E. S. G., Sattar, N. A., Preiss, D., Mancini, G. B. J., Ballantyne, C. M., Catapano, A. L., Gouni‐Berthold, I., et al. (2016) · Clinical Cardiology · doi:10.1002/clc.22518 · Cited by 42
Self-citation
Recommendations for Managing Drug–Drug Interactions with Statins and HIV Medications
Wiggins, B. S., Lamprecht, D. G., Page, R. L., II, & Saseen, J. J. (2017) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-017-0222-7 · Cited by 43
Toxic Myopathies
Doughty, C. T., & Amato, A. A. (2019) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000806 · Cited by 43
Rhabdomyolysis in a patient receiving atorvastatin and fluconazole
Kahri, J., Valkonen, M. M., B�cklund, T., Vuoristo, M., & Kivist, K. T. (2004) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-004-0858-5 · Cited by 43
Safety of Lovastatin/Extended Release Niacin Compared With Lovastatin Alone, Atorvastatin Alone, Pravastatin Alone, and Simvastatin Alone (from the United States Food and Drug Administration Adverse Event Reporting System)
Alsheikh-Ali, A. A. A., & Karas, R. H. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.08.044 · Cited by 43
Self-citation
Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting
Cziraky, M. J., Willey, V. J., McKenney, J. M., Kamat, S., Fisher, M. D., Guyton, J. R., Jacobson, T. A., & Davidson, M. H. (2012) · Journal of clinical lipidology · doi:10.1016/j.jacl.2012.06.006 · Cited by 42
Development and validation of a sensitive, simple, and rapid method for simultaneous quantitation of atorvastatin and its acid and lactone metabolites by liquid chromatography-tandem mass spectrometry (LC-MS/MS)
Macwan, J. S., Ionita, I. A., Dostálek, M., & Akhlaghi, F. (2011) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-011-4804-y · Cited by 43

Authors: Thompson, P. D., Clarkson, P., & Karas, R. H.
Affiliations: Hartford Hospital (US)
ORCID: Thompson, Paul D.
Karas, Richard H.
Venue: JAMA
Publisher: American Medical Association (AMA)
Published: 2003-04-02
Volume: 289
Issue: 13
Pages: 1681
ISSN: 0002-9955 (ISSN-L)
0098-7484
DOI: 10.1001/jama.289.13.1681
OpenAlex: W2059078444
Cited by: 1,463
References: 114
Citations by year: 2026: 8 · 2025: 22 · 2024: 31 · 2023: 27 · 2022: 30 · 2021: 33 · 2020: 38 · 2019: 54 · 2018: 52 · 2017: 54 · 2016: 79 · 2015: 60 · 2014: 76 · 2013: 75 · 2012: 97
FWCI: 19.53
Type: journal article
Language: en
Open access: closed
Locations: JAMA (publishedVersion)
PubMed (publishedVersion)
ScholarWorks@UMassAmherst (University of Massachusetts Amherst) (submittedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
Health Sciences › Medicine › Surgery › Muscle and Compartmental Disorders
Keywords: statin-induced myopathy, statins, rhabdomyolysis, myositis, creatine kinase elevation, myalgia, statin withdrawal, adverse drug reactions, cerivastatin, gemfibrozil, drug interactions
MeSH terms: Anticholesteremic Agents, Creatine Kinase, Humans, Muscle Cramp, Muscular Diseases, Myositis, Rhabdomyolysis, Adverse Drug Reaction Reporting Systems, Muscle, Skeletal, Muscle Weakness, Hydroxymethylglutaryl-CoA Reductase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Statin-Associated Myopathy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks